Aberrant SOX11 promoter methylation is associated with poor prognosis in gastric cancer

Abstract

Our results indicate that aberrant SOX11 gene promoter methylation may underlie its down-regulation in GC. SOX11 gene promoter hyper-methylation may serve as a biomarker to predict the clinical outcome of GC.

SOX11: a potentially useful marker in surgical pathology: a systematic analysis of SOX11 expression in epithelial and non‐epithelial tumours

“…Using IHC, reverse transcription–polymerase chain reaction (RT–PCR) or Western blot, SOX11 has been found to be down‐regulated in several malignant epithelial tumours, such as prostate, gastric and nasopharyngeal carcinomas via hypermethylation, and in these epithelial tumours SOX11 functions as a tumour suppressor gene that is associated with tumour growth and invasion . In this study, SOX11 expression was completely absent in all the aforementioned carcinomas, as well as most other adenocarcinomas and carcinomas that originated from the squamous, urinary and thymic epithelia using IHC (Table ).…”

“…Additionally, there are a few reports demonstrating SOX11 expression in mRNA and proteins of some malignant epithelial tumours. [14][15][16][17][18] However, the expression and significance of SOX11 using immunohistochemistry (IHC) analysis in different tumour types has not been thoroughly investigated.…”

Promoter hypermethylation of SOX11 correlates with adverse clinicopathological features of human prostate cancer

“…), gastric cancer (Xu et al . ) and nasopharyngeal carcinoma (Zhang et al . ), but not in prostate cancer cells or tissues.…”

“…SOX11 plays an important role in the development of the neural system (Hyodo-Miura et al 2002;Wang et al 2013). Several functional and clinicopathological studies demonstrated that SOX11 acts as a tumour suppressor in solid cancers (Hide et al 2009;Sernbo et al 2011;Zhang et al 2013;Xu et al 2015). Yao et al (2015) reported downregulation of SOX11 in prostate adenocarcinoma tissue compared to benign prostatic hyperplasia (BPH).…”

“…Promoter methylation of SOX11 has been studied in several cancers such as hematopoietic malignancies (Gustavsson et al 2010), ovarian cancer (Sernbo et al 2011), gastric cancer (Xu et al 2015) and nasopharyngeal carcinoma , but not in prostate cancer cells or tissues. Therefore, we aimed to investigate SOX11 promoter methylation in prostate adenocarcinoma and BPH with an emphasis on differential diagnosis between these lesions.…”